Summary A recent study showed an association between a single base substitution, T-*C, in the promotor region of the CYP17 gene, the risk of breast cancer and age at menarche in Asian, African-American and Latino women from California and Hawaii. The C allele was associated with increased risk of breast cancer, significantly so for patients presenting with advanced disease, whereas the TT genotype was associated with later age at menarche in control subjects. We attempted to confirm these findings in a large case-control study in East Anglia, England (835 cases and 591 control subjects). We found no evidence of an increased risk of breast cancer [odds ratio (OR) 1.10, confidence interval (Cl) 0.89-1.37] or advanced breast cancer (OR 0.88, Cl 0.38-2.01) in C allele carriers, nor any association between age at menarche and genotype. We conclude that these alleles do not significantly alter breast cancer risk in the English population.
Epidemiological and laboratory studies indicate that breast cancer risk is strongly related to hormonal factors, specifically exposure to endogenous oestrogens. Ecological studies indicate that hormone levels are strongly influenced by lifestyle factors (e.g. diet), but genetic factors could also be important. This raises the possibility that polymorphisms in genes involved in sex steroid hormone metabolism may have a role in breast cancer susceptibility. One such gene is CYPI 7, which encodes an enzyme, cytochrome P450cl7a. This enzyme has two different roles in steroid interconversion: the 17ax hydroxylase activity can convert progesterone to 17a-hydroxyprogesterone, and the 17,20 lyase function may further convert 17a-hydroxyprogesterone to androstenedione (the precursor of both oestrone and testosterone). There is a polymorphic T to C substitution 34 bp upstream of the translation initiation site in the promotor region of the gene, which creates an MspAl restriction site (Carey et al, 1997) . This substitution also creates a fifth SpI-type (CCACC) motif in the 5' region of the CYPI 7 gene. It is thought that gene transcription may correlate with the number of these motifs, and so this polymorphism has the potential to alter the promotor activity and possibly also the production rate of CYPI 7.
Two association studies using this CYP17 MspAl restriction fragment length polymorphism (RFLP) have been published to date. One study investigated the association between genotype and polycystic ovary and male pattern baldness (Carey et al, 1997) . Carriers of the C allele were found to have a twofold increased risk of either polycystic ovary disease or male pattern baldness, depending on sex. More recently, Feigelson et al (1997) reported an association of the same C (A2) allele with an increased risk of breast cancer, which was significant only in patients presenting with advanced breast cancer. They also found that within their control group the TT (Al) homozygotes had a later age at menarche than carriers of the C allele and they suggested that the reduced risk of breast cancer associated with later age at menarche is limited to TT homozygous women. However, this study was performed using only 174 breast cancer cases and 285 control subjects from three different ethnic groups and significant results were only demonstrated in subgroup analyses. We set out to confirm these findings in a much larger case-control study from the East Anglian region of England.
MATERIALS AND METHODS
Case and control subject selection Cases were taken from a population-based study of breast cancer. All women in the region served by the Anglian cancer registry with breast cancer diagnosed between 1 January 1991 and 30 June 1996 who were under the age of 55 at diagnosis were eligible to take part. Genotyping was carried out on the first 864 samples received from 2007 eligible patients. Control subjects were randomly selected from the UK part of the European Prospective Investigation of Cancer (EPIC) (Riboli and Kaaks, 1997) , a prospective study of diet and cancer being carried out in the same population from which the cases have been drawn. The EPIC cohort comprises 25 000 individuals resident in Norfolk (East Anglia), aged 45-74 years.
Genotype detection The CYP17, 5'-utr, MspAl polymorphism assay has been described previously (Carey et al, 1997; Feigelson et al, 1997) . Briefly, a 459-bp polymerase chain reaction (PCR) product was amplified using the following primer pair: CYPI 7-F, 5'-CATTCG-CACCTCTGGAGTC and CYPJ7-R, 5'-GGCTCTTGGGGTAC-TTG, and the following conditions on a TouchDown thermal *Contributed equally to this study. 
Statistical analysis
The association between CYP17 alleles and breast cancer was assessed using X2 tests. For the three-way comparison between genotype and risk of breast cancer, variances were estimated by treating odds ratios as floating absolute risks (Easton et al, 1991 95 (12.56-13.34) in CC homozygotes (oneway ANOVA, P = 0.77). In addition, there was no significant association between genotype and age at first full-term pregnancy or parity.
The relative risks of breast cancer associated with late age at menarche (. 13 years) stratified by genotype are shown in Table 2 . We found a non-significant reduction in breast cancer risk in individuals with late age at menarche. There was no difference in this risk when stratified by genotype, a finding consistent with the lack of association between genotype and age at menarche in control subjects.
DISCUSSION
We found no significant effect of the CYPJ7 promotor T to C substitution on breast cancer risk in a large case-control study, nor have we been able to confirm the previously reported association between the CYPJ 7 genotype and risk of advanced breast cancer: Feigelson et al (1997) reported a significant association of the C allele with advanced disease (OR 2.5, 95% CI 1.07-5.94), indicating that disease progression may be more rapid in carriers of the C allele. In contrast, we found a reduced risk of advanced disease in C allele carriers. However, the number of cases with advanced disease in each study was small, the associated confidence intervals are wide and there was no significant difference between the two risk estimates (X2 = 3.00, P = 0.082). Combining the data from the two studies gives an OR for advanced cancer in women carrying the C allele of 1.57 (0.89-2.90), and so the data are compatible with a small increase in risk of advanced cancer. A larger study addressing the issue of cancer progression would be required to confirm this.
Late age at menarche has been shown to be associated with a reduced risk of breast cancer (Kelsey et al, 1993) , and the results of this study are consistent with this effect. Unlike Feigelson et al (1997) we found no effect of genotype on age at menarche. In our control subjects, mean age at menarche was 0.02 years (95% CI -0.30 to 0.27) earlier in TT homozygotes than in women carrying a C (A2) allele, whereas Feigelson et al reported that the mean age at menarche in TT (AlAl) women was 0.4 years later. From our result we would not expect to find an effect of genotype on risk of breast cancer associated with late age at menarche, and no such effect was demonstrated.
Our study had an 80% power to detect a 1.3-fold increased risk in C-allele carriers at a significance level of 5%, which is the magnitude of the effect reported in the study by Feigelson et al (1997) . However, we failed to confirm their reported association between CYPI 7 genotype, age at menarche and breast cancer risk. There are several possible explanations for the difference between our results and those of Feigelson et al. The ethnic background of the two study populations are different (the population of East Anglia is close to 100% white), and, although the CYPI 7 genotype distribution in East Anglia is similar to that of the American control subjects, there is the potential for as yet unidentified gene-gene interactions between CYP17 and genes that differ in Polymorphism in CYPl 7 and breast cancer 2047 frequency in the two populations. Alternatively, it is possible that the T-C substitution is not in itself disease causing, but in some populations is in linkage disequilibrium with another alteration that is disease causing. If this were true, then the association would only be apparent in those populations. Another possible explanation is that genotype effects are age specific, with a marked effect only in older cases. Further studies of older cases would be needed to address this possibility. The most likely explanation is that the original study was small and the positive associations reported were chance findings that have not been confirmed by a larger and more powerful study.
